Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group (NCCTG).

被引：0

作者：

Witzig, TE

Vukov, AM

Habermann, TM

Geyer, S

Friedenberg, WR

White, WL

Salim, M

Flynn, PJ

Fitch, TR

Morton, RF

机构：

[1] Mayo Clin, Rochester, MN USA

[2] OHACI, Peoria, IL USA

[3] Guthrie Clin, Milan, Italy

[4] Allan Blair Canc Ctr, Regina, SK, Canada

[5] Oncolog Consultants PA, Minneapolis, MN USA

[6] Mayo Clin, Scottsdale, AZ USA

[7] Iowa Oncol Res Assoc CCOP, Med Oncol & Med Assoc, Des Moines, IA USA

来源：

BLOOD | 2002年 / 100卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1398

引用

页码：361A / 361A

页数：1

共 50 条

[41] Phase II study of combination immunotherapy with interleukin-2 (IL-2) and rituximab in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (NHL).
Friedberg, JW
Neuberg, D
Gribben, JG
Canning, C
Daley, JF
Kuhlman, C
Koval, M
Donovan, J
Soiffer, RJ
Freedman, AS
BLOOD, 2000, 96 (11) : 730A - 731A
[42] Phase I/II trial epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL).
Leonard, JP
Coleman, M
Matthews, JC
Chadburn, A
Wegener, WA
Hansen, HJ
Ziccardi, H
Kapushoc, H
Gayko, U
Cesano, A
Fields, SZ
Goldenberg, DM
BLOOD, 2002, 100 (11) : 358A - 358A
[43] Iodine I 131 tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology.
Vose, JM
Zelenetz, AD
Rohatiner, A
Knox, S
Stagg, R
Kroll, S
Tidmarsh, G
Kaminski, MS
BLOOD, 1999, 94 (10) : 89A - 89A
[44] IMMUNO-CHEMOTHERAPY WITH RITUXIMAB-CHOP IN A HEMODIALYSIS PATIENT WITH A NEWLY DIAGNOSED FOLLICULAR IIIA GRADE B-CELL NON-HODGKIN'S LYMPHOMA
Giglio, G.
Antrilli, A.
Pollio, A. M.
Brigante, M.
Romito, S.
HAEMATOLOGICA, 2008, 93 : S139 - S139
[45] Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL).
Ansell, SM
Witzig, TE
Kurtin, PJ
Jelinek, DF
Howell, KG
Markovic, SN
Habermann, TM
Klee, GG
Sloan, JA
Erlichmann, C
BLOOD, 2000, 96 (11) : 577A - +
[46] Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
Alberts, SR
Townley, PM
Goldberg, RM
Cha, SS
Moore, DF
Krook, JE
Pitot, HC
Fitch, TR
Wiesenfeld, M
Mailliard, JA
Sargent, DJ
ANNALS OF ONCOLOGY, 2002, 13 (04) : 553 - 557
[47] Utilization of rituximab therapy in patients (pts) with newly diagnosed follicular (FL) and diffuse large B cell (DLCL) non-Hodgkin's lymphoma (NHL) in the United States: An analysis from the national comprehensive cancer network (NCCN) NHL outcomes project.
Friedberg, JW
Lepisto, E
Rodriguez, MA
Ottensen, R
LaCasce, AS
Nademanee, AP
Millenson, M
Czuczman, M
Niland, J
Zelenetz, AD
Weeks, J
BLOOD, 2003, 102 (11) : 494A - 494A
[48] Phase I/II study of THP-COP therapy for old-age patients with advanced stage aggressive non-Hodgkin's lymphoma (NHL): Of lymphoma phase I study group (LPOSG) study on 30 patients older than 70 years.
Ogura, M
Kagami, Y
Hirose, T
Chou, T
Nagai, H
Kinoshita, T
Ohnishi, K
Ohmachi, K
Hotta, T
BLOOD, 2001, 98 (11) : 245B - 245B
[49] Rituximab:: Pharmacokinetic/pharmacodynamic correlations of extended dosing in patients (pts) with relapsed low-grade or follicular non-Hodgkin's lymphoma (LG/F NHL).
Saven, A
Grillo-López, AJ
Janakiraman, N
Alkuzweny, B
Beck, TM
Piro, L
Rosenberg, J
McClure, A
White, CA
BLOOD, 2000, 96 (11) : 730A - 730A
[50] Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE
Nowakowski, Grzegorz S.
LaPlant, Betsy
Macon, William R.
Gertz, Morie A.
Habermann, Thomas Matthew
Inwards, David James
Micallef, Ivana N. M.
Wender, Donald B.
Leonard, John
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →